Steward Partners Investment Advisory LLC Purchases 10,700 Shares of PLx Pharma Inc. (NASDAQ:PLXP)

Steward Partners Investment Advisory LLC increased its position in PLx Pharma Inc. (NASDAQ:PLXPGet Rating) by 18.0% in the 1st quarter, Holdings Channel reports. The firm owned 70,148 shares of the biotechnology company’s stock after buying an additional 10,700 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in PLx Pharma were worth $283,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Commonwealth Equity Services LLC lifted its holdings in shares of PLx Pharma by 24.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 37,222 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 7,421 shares during the period. Qube Research & Technologies Ltd bought a new position in shares of PLx Pharma during the fourth quarter valued at $310,000. Eidelman Virant Capital lifted its holdings in shares of PLx Pharma by 54.3% during the fourth quarter. Eidelman Virant Capital now owns 27,000 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 9,500 shares during the period. First Republic Investment Management Inc. lifted its holdings in shares of PLx Pharma by 32.7% during the fourth quarter. First Republic Investment Management Inc. now owns 283,517 shares of the biotechnology company’s stock valued at $2,271,000 after acquiring an additional 69,862 shares during the period. Finally, Ground Swell Capital LLC lifted its holdings in shares of PLx Pharma by 20.6% during the fourth quarter. Ground Swell Capital LLC now owns 36,407 shares of the biotechnology company’s stock valued at $292,000 after acquiring an additional 6,221 shares during the period. 44.19% of the stock is owned by institutional investors.

PLx Pharma Stock Performance

Shares of NASDAQ PLXP opened at $2.22 on Friday. The stock has a market cap of $61.14 million, a PE ratio of -0.82 and a beta of 4.08. The business has a fifty day moving average of $2.28 and a two-hundred day moving average of $3.70. PLx Pharma Inc. has a 52-week low of $1.81 and a 52-week high of $21.19.

PLx Pharma (NASDAQ:PLXPGet Rating) last issued its quarterly earnings data on Friday, May 13th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.03. The company had revenue of $2.08 million for the quarter, compared to the consensus estimate of $2.35 million. Analysts predict that PLx Pharma Inc. will post -2.03 earnings per share for the current year.

About PLx Pharma

(Get Rating)

PLx Pharma Inc operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules.

Further Reading

Want to see what other hedge funds are holding PLXP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PLx Pharma Inc. (NASDAQ:PLXPGet Rating).

Institutional Ownership by Quarter for PLx Pharma (NASDAQ:PLXP)

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.